Back to search results

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Myeloid Malignancy · Hematologic Malignancy · Acute Myeloid Leukemia · Myelodysplastic Syndromes

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Margaret Thomas, MPH) · margaretannthomas@uabmc.edu
    Zaid Al-Kadhimi, MD (Sub-investigator)
    Ravi Bhatia, MD (Sub-investigator)
    Antonio Di Stasi, MD (Sub-investigator)
    Manuel Espinoza-Gutarra, MD (Sub-investigator)
    Donna Salzman, MD (Sub-investigator)
    Lauren Shea, MD (Sub-investigator)
Study leads

  • Omer A Jamy, MD

    Principal Investigator

    The University of Alabama at Birmingham

View source on ClinicalTrials.gov(opens in a new tab)